Danwang Medical Secures Tens of Millions of Yuan in Series Angel Funding to Advance Clinical Development of Organoid Technology

VCBeat (WeChat ID: vcbeat) has learned that Danwang Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Danwang Medical”) recently announced the completion of its angel round financing, amounting to tens of millions of yuan. The round was led by CoWin Ventures, with Lingxian Health participating as a co-investor. The funds raised will be primarily used to build Danwang Medical’s standardized organoid system, upgrade product research and development, promote business implementation, and strategically lay out commercial services.

Danwang Medical is dedicated to the development and application of organoid technology, with a focus on precision diagnosis and treatment of tumors. By concentrating on the clinical development and application of organoid technology, Danwang Medical provides patients with new technologies and treatment plans for personalized diagnosis, and offers pharmaceutical R&D enterprises a precise, efficient, and high-quality organoid service platform. Leveraging its robust organoid technology platform, Danwang Medical has optimized and established standard operating procedures and quality systems for organoid culture that meet the requirements for both clinical diagnosis and drug screening. The company has collaborated with multiple Grade A tertiary hospitals to conduct clinical validation studies related to organoids.

Dr. Hua Guoqiang, Founder of Danwang MedicalHe stated, “The participation of CoWin Ventures and Lingxian Health Fund will facilitate the efficient integration of capital and technology, accelerating Danwang Medical’s technological innovation and development in the organoid field. Over the past few years, our team at Danwang has been deeply committed to and focused on innovating organoid technology. From the invention and innovation of organoid techniques to clinical validation trials, we have built a diversified, open ecosystem for industry-academia-research collaboration. We have established extensive partnerships with numerous domestic and international research institutions, hospitals, and pharmaceutical companies, laying a substantial foundation for our basic research and clinical applications in the organoid sector. Currently, Danwang Medical has successfully established organoids for multiple tissues and organs, as well as tumor organoids derived from corresponding tissues, including those for colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, and bladder cancer. This financing round will accelerate the prospective clinical validation trials of Danwang’s tumor organoids and the establishment of a standardized organoid system.”

Professor Hans Clevers, Founder of Danwang MedicalHe stated, “Since 2009, organoids have been increasingly adopted by researchers and pharmaceutical companies for precision medicine and drug development, owing to the inherent advantages of their technological models. Danwang Medical is a pioneer in China’s organoid field. Its founding team has accumulated nearly a decade of expertise in organoid technology and possesses profound capabilities in organoid-based precision medicine and regenerative medicine, which was precisely why I joined Danwang. The advancement and clinical application of organoid technology require the participation and support of capital from the healthcare sector. Moreover, companies themselves must adhere to rigorous scientific development principles, establishing standards and high-quality quality control for organoids. It is gratifying to witness the robust growth of organoid technology in China. Furthermore, China enjoys favorable conditions for leapfrog development in this field, such as advantages in biological sample availability and a vast patient population. We will accelerate our R&D efforts in standardizing organoid culture techniques and developing clinical test kits, aiming to bring organoid-based technologies into clinical diagnosis and treatment for patients as soon as possible.”

Li Junqiang, Founder and CEO of Danwang Medical“The company stated: ‘We extend our gratitude to CoWin Ventures and Lingxian Health for their recognition of Danwang’s organoid technology and development philosophy. Danwang Medical is committed to innovation in organoid technology and its clinical applications. Upholding an innovation-driven strategy for corporate growth, we will continuously enhance our innovative capabilities and accelerate the clinical adoption of organoids. The funds from this financing round will be utilized to accelerate the establishment of a standardized organoid system, develop quality standards, promote diversified business models, and expand commercial channels, thereby supporting Danwang Medical in building the premier organoid technology platform in China and globally. The company will continue to deepen its expertise in the organoid field, constantly explore technological innovations, and accumulate application capabilities, making sustained contributions to the advancement of the global precision medicine industry.’”

Dr. Huang Xin, Managing Partner of CoWin Ventures“The statement reads: ‘As the most prominent emerging life science technology in recent years, organoids offer irreplaceable advantages in the field of precision medicine. Organoid technology holds immense commercial potential, both in clinical applications and drug development. Danwang Medical has established a clear and precise positioning and strategic direction in the organoid sector, with values that align closely with the investment philosophy of CoWin Ventures. We are optimistic about Danwang Medical’s global vision, its layout for standardization, accumulated R&D capabilities, and innovative business model. With a professional and efficient team, bolstered by the addition of Hans Clevers, the pioneer of international organoid technology, we look forward to Danwang Medical leveraging the momentum of the upgraded Healthy China strategy to build a globally leading service platform in the organoid field and drive the development of the precision medicine industry.’”

Dr. Wu Jialu, Lead Health Management Partner“The invention and application of organoid technology have enabled breakthrough progress in precision oncology treatment and drug development. We have consistently taken the lead in focusing on technological advancements in organoids, believing that organoid models are poised to become a new cornerstone in the field of medicine and healthcare. Danwang Medical holds significant advantages in original, in-depth organoid technology and clinical trials, positioning it as a leader in the organoid sector. As a partner in Danwang’s angel funding round, we are confident in our ability to support the company’s growth and serve as a valuable strategic ally. We wish Danwang every success in becoming a unicorn in the organoid field at an early stage.”

Danwang Medical Technology (Shanghai) Co., Ltd. is located in the Shanghai Nanxiang Precision Medicine Industrial Park. The company is dedicated to translating leading organoid technologies into clinical applications, including disease diagnosis and treatment, new drug screening, and the development and identification of tumor markers. It provides personalized precision treatment plans for clinical patients while offering precise, efficient, and high-quality organoid models for new drug research and development. Danwang possesses a globally leading innovation platform for organoid technology and has established organoid culture systems for both normal and tumor tissues of multiple human organs, including the lung, pancreas, breast, stomach, intestine, and liver, positioning itself as a pioneer in the field of organoids.

CoWin Ventures is a Sino-US dual-currency venture capital firm focused on investing in early-stage technology companies, advocating a team culture of equality, transparency, sharing, and innovation. Established in 2009, the firm concentrates on the healthcare and IT hard-tech sectors. It has independently managed 17 funds with cumulative assets under management exceeding RMB 5 billion, providing financial and resource support to more than 100 outstanding teams and projects. CoWin Ventures has empowered numerous enterprises to stand out in their respective niches, including Taimei Medical Technology, Zhenhe Technology, Huake Jingzhun, Thrive, and Cytek. Additionally, it has facilitated the successful public listings of over ten high-tech companies, such as Zhongji Innolight (300308), Microsens Semiconductor (688286), Neusoft Reach (300183), Huaxing Zhiyuan (000008), Aolian Electronics (300585), and Sanxin Advanced Materials (300554).

Linghang Health is a venture capital fund founded by seasoned medical investment professionals, dedicated to early-stage investments in the healthcare and medical industry. Adhering to the philosophy of “Focus and Professionalism,” we deeply explore development trends and investment opportunities within the sector, filtering out noise and distractions to pursue genuine investment returns.